Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Mantle Cell Lymphoma: From Biology to Therapy
share announcement

Mantle Cell Lymphoma: From Biology to Therapy

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".

Deadline for manuscript submissions: closed (25 December 2024) | Viewed by 4183

Special Issue Editor

Dr. Narendranath Epperla

E-Mail Website
Guest Editor
The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA
Interests: aggressive non-Hodgkin lymphomas; indolent non-Hodgkin lymphomas; Hodgkin lymphoma; Waldenstrom macroglobulinemia; targeted therapies; cellular therapies; CART
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Mantle cell lymphoma (MCL) is a heterogeneous disease comprising around 2.5–6% of B-cell non-Hodgkin lymphoma cases. The primary genetic alteration in MCL is chromosomal translocation (11;14) which leads to CyclinD1 overexpression and uncontrolled cell proliferation. There are several variants of MCL including leukemic non-nodal, classic, blastoid, and pleomorphic, which have varying biological characteristics that lead to different disease courses and long-term outcomes. There are several independent prognostic factors in MCL including the MIPI, MIPI-b, Ki-67%>30%, TP53 mutation, SOX11 expression, complex cytogenetics, and MCL35 assay with several other factors/risk scores currently under evaluation.

The survival of patients with MCL has significantly improved over the past decade due to better understanding of the disease biology and the advent of targeted therapies. Small-molecule inhibitors such as proteasome inhibitors, immunomodulators, BTK inhibitors, and BCL2 inhibitors either alone or in combination have changed the treatment landscape and outcomes regarding this disease. Several other antibody–drug conjugates, cell cycles, and intracellular signaling inhibitors are currently under evaluation. More recently, CD19-directed CART cell therapy and bispecific antibodies have ushered an era of cellular therapies in MCL with remarkable outcomes, even in high-risk subsets.

In this issue, we will focus on the advancements made in the field of MCL starting with biology and discussing the current and emerging therapies in light of these advancements.   

Dr. Narendranath Epperla
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • MCL
  • biology
  • BTK inhibitors
  • BCL2 inhibitors
  • CART
  • bispecific antibodies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

27 pages, 1169 KiB  
Review
Updates on the Biological Heterogeneity of Mantle Cell Lymphoma
by Andrew Ip, Maciej Kabat, Lindsay Fogel, Hassan Alkhatatneh, Jason Voss, Amolika Gupta, Alexandra Della Pia, Lori A. Leslie, Tatyana Feldman, Maher Albitar and Andre H. Goy
Cancers 2025, 17(4), 696; https://doi.org/10.3390/cancers17040696 - 19 Feb 2025
Viewed by 498
Abstract
Advancements in mantle cell lymphoma (MCL) have illuminated the disease’s molecular diversity, leading to a wide variation in the outcomes observed in MCL. Current prognostic risk scores are continuously revised to incorporate new updates in the mechanistic or biologic understanding of MCL. Nevertheless, [...] Read more.
Advancements in mantle cell lymphoma (MCL) have illuminated the disease’s molecular diversity, leading to a wide variation in the outcomes observed in MCL. Current prognostic risk scores are continuously revised to incorporate new updates in the mechanistic or biologic understanding of MCL. Nevertheless, key high-risk features of MCL associated with rapid disease progression and poor survival, such as TP53 mutations, complex karyotypes, and blastoid or pleomorphic morphologies, remain absent from available prognostic tools. The greater accessibility of genomic technologies, such as next-generation sequencing (NGS), has enabled clinicians to identify specific genetic alterations that serve as prognostic signals and disease monitoring parameters, cultivating accurate risk profiling that is illustrative of MCL heterogeneity. Through an increased understanding of distinct MCL behaviors, novel therapies that mechanistically target disease biology, including Bruton’s tyrosine kinase inhibitors, BCL-2 inhibitors, ROR1 inhibitors, and bispecific T-cell engagers, have broadened the treatment armamentarium for relapsed/refractory MCL cases. These interventions, in addition to chemoimmunotherapy and autologous stem cell transplantation mainstays, confer the individualization of treatment and improved survival outcomes. Further exploration of the considerable biological heterogeneity of MCL can enhance knowledge, management, and the treatment of this rare lymphoma subtype. Full article
(This article belongs to the Special Issue Mantle Cell Lymphoma: From Biology to Therapy)
►▼ Show Figures

Figure 1

17 pages, 306 KiB  
Review
Targeted Therapies in the Treatment of Mantle Cell Lymphoma
by Colin J. Thomas, Veronica Carvajal and Stefan K. Barta
Cancers 2024, 16(10), 1937; https://doi.org/10.3390/cancers16101937 - 20 May 2024
Viewed by 2972
Abstract
Mantle cell lymphoma (MCL) is a rare, heterogeneous B-cell non-Hodgkin’s lymphoma. The standard front-line treatment utilizes chemotherapy, often followed by consolidation with an autologous hematopoietic cell transplant; however, in most patients, the lymphoma will recur and require subsequent treatments. Additionally, mantle cell lymphoma [...] Read more.
Mantle cell lymphoma (MCL) is a rare, heterogeneous B-cell non-Hodgkin’s lymphoma. The standard front-line treatment utilizes chemotherapy, often followed by consolidation with an autologous hematopoietic cell transplant; however, in most patients, the lymphoma will recur and require subsequent treatments. Additionally, mantle cell lymphoma primarily affects older patients and is frequently chemotherapy-resistant, which has further fostered the necessity for new, chemotherapy-free treatment options. In the past decade, targeted therapies in mantle cell lymphoma have been practice-changing as the treatment paradigm shifts further away from relying primarily on cytotoxic agents. Here, we will review the pathophysiology of mantle cell lymphoma and discuss the emergence of targeted, chemotherapy-free treatments aimed at disrupting the abnormal biology driving its lymphomagenesis. Treatments targeting the constitutive activation of NF-kB, Bruton’s Tyrosine Kinase signaling, and anti-apoptosis will be the primary focus as we discuss their clinical data and toxicities. Our review will also focus primarily on the emergence and use of targeted therapies in the relapsed/refractory setting but will also discuss the emergence of their use in front-line therapy and in combination with other agents. Full article
(This article belongs to the Special Issue Mantle Cell Lymphoma: From Biology to Therapy)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop